Human Cytomegalovirus Infection in Solid-Organ Transplantation.
- Author:
Yong Hee KIM
1
Author Information
- Publication Type:Review
- Keywords: Cytomegalovirus; Organ transplantation; Immunocompromised hosts
- MeSH: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections*; Drug Resistance; Ganciclovir; Graft Rejection; Humans; Immunocompromised Host; Opportunistic Infections; Organ Transplantation; Transplantation
- From:Journal of Bacteriology and Virology 2015;45(1):11-18
- CountryRepublic of Korea
- Language:English
- Abstract: Human cytomegalovirus (CMV) continues to be a major threat against solid-organ transplant recipients despite significant advancements in its prophylaxis and therapy. Primary CMV infection or reactivation of latent CMV in the transplant recipients may cause CMV diseases such as flu-like viral syndrome and tissue-invasive CMV disease. In addition, CMV infection in the recipients is associated with graft rejection and higher risk of other opportunistic infections, which are collectively known as the "indirect effects" of CMV infection. Prevention strategies with antiviral drugs including ganciclovir remarkably decreased CMV disease and the "indirect effects". Two commonly employed strategies are universal prophylaxis and preemptive therapy. However, gangciclovir-resistant CMV has emerged due to mutations in CMV UL97 and UL54 genes, now requiring alternative therapeutic options to be developed. This review provides an overview of CMV infection and disease, "indirect effects" on hosts, prevention strategies, and drug resistance in solid-organ transplant recipients.
